The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Evaluating the benefit-risk balance of second-line therapies for HR+/HER2- metastatic breast cancer: A comparative analysis using ASCO VF and ESMO MCBS frameworks.
 
Alessandra Longobardi
No Relationships to Disclose
 
Roberto Buonaiuto
No Relationships to Disclose
 
Aldo Caltavituro
No Relationships to Disclose
 
Giuseppina Crimaldi
No Relationships to Disclose
 
Vincenza Cantile
No Relationships to Disclose
 
Vittoria Molinaro
No Relationships to Disclose
 
Federica P. Mangiacotti
No Relationships to Disclose
 
Angela Grieco
No Relationships to Disclose
 
Martina Di Meo
No Relationships to Disclose
 
Martina Pagliuca
Travel, Accommodations, Expenses - Gilead Sciences
 
Valeria Forestieri
No Relationships to Disclose
 
Mario Giuliano
No Relationships to Disclose
 
Michelino De Laurentiis
Stock and Other Ownership Interests - Arvinas
Honoraria - AstraZeneca; Daiichi Sankyo Europe GmbH; Exact Sciences; Gilead Sciences; Ipsen; Lilly; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Seagen; TOMA Biosciences; Veracyte
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo Europe GmbH; Gilead Sciences; Ipsen; Lilly; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Speakers' Bureau - Novartis
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Genzyme (Inst); Lilly; MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
 
Grazia Arpino
Honoraria - AstraZeneca; Lilly; Novartis; Novartis (Inst); Pfizer; Pfizer (Inst); Roche
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Eisai; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Speakers' Bureau - Helsinn Therapeutics/QED Therapeutics; Lilly; Novartis; Pfizer; Roche
Research Funding - eisai (Inst); Novartis (Inst); pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo/Astra Zeneca; Lilly; Pfizer; Roche
 
Carmine De Angelis
No Relationships to Disclose